KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Total Liabilities (2018 - 2025)

Historic Total Liabilities for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $286.4 million.

  • Adaptive Biotechnologies' Total Liabilities fell 1450.29% to $286.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $286.4 million, marking a year-over-year decrease of 1450.29%. This contributed to the annual value of $336.9 million for FY2024, which is 452.45% down from last year.
  • As of Q3 2025, Adaptive Biotechnologies' Total Liabilities stood at $286.4 million, which was down 1450.29% from $317.1 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Total Liabilities high stood at $396.4 million for Q3 2022, and its period low was $286.4 million during Q3 2025.
  • For the 5-year period, Adaptive Biotechnologies' Total Liabilities averaged around $339.9 million, with its median value being $341.1 million (2021).
  • In the last 5 years, Adaptive Biotechnologies' Total Liabilities tumbled by 1521.68% in 2022 and then skyrocketed by 2783.6% in 2023.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Total Liabilities stood at $319.2 million in 2021, then grew by 22.95% to $392.5 million in 2022, then dropped by 10.1% to $352.9 million in 2023, then fell by 4.52% to $336.9 million in 2024, then dropped by 15.0% to $286.4 million in 2025.
  • Its last three reported values are $286.4 million in Q3 2025, $317.1 million for Q2 2025, and $320.6 million during Q1 2025.